243 related articles for article (PubMed ID: 30613765)
1. IDH3α regulates one-carbon metabolism in glioblastoma.
May JL; Kouri FM; Hurley LA; Liu J; Tommasini-Ghelfi S; Ji Y; Gao P; Calvert AE; Lee A; Chandel NS; Davuluri RV; Horbinski CM; Locasale JW; Stegh AH
Sci Adv; 2019 Jan; 5(1):eaat0456. PubMed ID: 30613765
[TBL] [Abstract][Full Text] [Related]
2. An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells.
Miyata S; Urabe M; Gomi A; Nagai M; Yamaguchi T; Tsukahara T; Mizukami H; Kume A; Ozawa K; Watanabe E
Neurol Med Chir (Tokyo); 2013; 53(10):645-54. PubMed ID: 24077277
[TBL] [Abstract][Full Text] [Related]
3. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
4. Aberrant IDH3α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis.
Zeng L; Morinibu A; Kobayashi M; Zhu Y; Wang X; Goto Y; Yeom CJ; Zhao T; Hirota K; Shinomiya K; Itasaka S; Yoshimura M; Guo G; Hammond EM; Hiraoka M; Harada H
Oncogene; 2015 Sep; 34(36):4758-66. PubMed ID: 25531325
[TBL] [Abstract][Full Text] [Related]
5. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
[TBL] [Abstract][Full Text] [Related]
6. Glutamate and α-ketoglutarate: key players in glioma metabolism.
Maus A; Peters GJ
Amino Acids; 2017 Jan; 49(1):21-32. PubMed ID: 27752843
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation.
Zhang D; Wang Y; Shi Z; Liu J; Sun P; Hou X; Zhang J; Zhao S; Zhou BP; Mi J
Cell Rep; 2015 Mar; 10(8):1335-48. PubMed ID: 25732824
[TBL] [Abstract][Full Text] [Related]
8. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
Krell D; Assoku M; Galloway M; Mulholland P; Tomlinson I; Bardella C
PLoS One; 2011; 6(5):e19868. PubMed ID: 21625441
[TBL] [Abstract][Full Text] [Related]
9. Mitochondria-targeting nano therapy altering IDH2-mediated EZH2/EZH1 interaction as precise epigenetic regulation in glioblastoma.
Kaundal B; Karmakar S; Roy Choudhury S
Biomater Sci; 2022 Sep; 10(18):5301-5317. PubMed ID: 35917200
[TBL] [Abstract][Full Text] [Related]
10. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
Gonthier K; Weidmann C; Berthiaume L; Jobin C; Lacouture A; Lafront C; Harvey M; Neveu B; Loehr J; Bergeron A; Fradet Y; Lacombe L; Riopel J; Latulippe É; Atallah C; Shum M; Lambert JP; Pouliot F; Pelletier M; Audet-Walsh É
Mol Oncol; 2023 Oct; 17(10):2109-2125. PubMed ID: 37086156
[TBL] [Abstract][Full Text] [Related]
12. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.
Calvert AE; Chalastanis A; Wu Y; Hurley LA; Kouri FM; Bi Y; Kachman M; May JL; Bartom E; Hua Y; Mishra RK; Schiltz GE; Dubrovskyi O; Mazar AP; Peter ME; Zheng H; James CD; Burant CF; Chandel NS; Davuluri RV; Horbinski C; Stegh AH
Cell Rep; 2017 May; 19(9):1858-1873. PubMed ID: 28564604
[TBL] [Abstract][Full Text] [Related]
13. A Sox2:miR-486-5p Axis Regulates Survival of GBM Cells by Inhibiting Tumor Suppressor Networks.
Lopez-Bertoni H; Kotchetkov IS; Mihelson N; Lal B; Rui Y; Ames H; Lugo-Fagundo M; Guerrero-Cazares H; Quiñones-Hinojosa A; Green JJ; Laterra J
Cancer Res; 2020 Apr; 80(8):1644-1655. PubMed ID: 32094299
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
Doll S; Urisman A; Oses-Prieto JA; Arnott D; Burlingame AL
Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
[TBL] [Abstract][Full Text] [Related]
16. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
17. Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma.
Fukunaga T; Fujita Y; Kishima H; Yamashita T
PLoS One; 2018; 13(11):e0206552. PubMed ID: 30388142
[TBL] [Abstract][Full Text] [Related]
18. The role of NAD(+)-dependent isocitrate dehydrogenase 3 subunit α in AFB1 induced liver lesion.
Yang C; Fan J; Zhuang Z; Fang Y; Zhang Y; Wang S
Toxicol Lett; 2014 Jan; 224(3):371-9. PubMed ID: 24211421
[TBL] [Abstract][Full Text] [Related]
19. YAP promotes autophagy and progression of gliomas via upregulating HMGB1.
Zhao M; Zhang Y; Jiang Y; Wang K; Wang X; Zhou D; Wang Y; Yu R; Zhou X
J Exp Clin Cancer Res; 2021 Mar; 40(1):99. PubMed ID: 33726796
[TBL] [Abstract][Full Text] [Related]
20. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
